217 results
8-K
EX-99.1
MDXG
Mimedx Group Inc
30 Apr 24
MIMEDX Announces First Quarter 2024 Operating and Financial
4:10pm
of intangible assets
Interest expense, net
Income tax provision (benefit) expense
Share-based compensation
Investigation, restatement and related expenses … .
Research and development expenses were $3 million for each of the three months ended March 31, 2024 and March 31, 2023.
Investigation, restatement
8-K
EX-99.1
MDXG
Mimedx Group Inc
28 Feb 24
MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results
4:22pm
Income tax provision (benefit) expense
Investigation, restatement and related expenses
Share-based compensation
Expenses related to disbanding … in the portfolio - AMNIOEFFECT, AXIOFILL and EPIEFFECT - along with additional early-stage Wound & Surgical products in development.
Investigation
8-K
EX-99.2
nc7odwtj
13 Nov 23
MIMEDX to Participate in Upcoming Investor Conferences
8:14am
8-K
EX-99.1
v977 2kcx
30 Oct 23
MIMEDX Announces Third Quarter 2023 Operating and Financial Results
4:05pm
8-K
EX-99.2
9c8ix1m2ie j2v9vf
5 Sep 23
MIMEDX to Present at Upcoming Investor Conferences
8:38am
8-K
EX-99.1
vsze5f
1 Aug 23
MIMEDX Announces Second Quarter 2023 Operating and Financial Results
4:03pm
8-K
EX-99.2
86fzbt
1 Aug 23
MIMEDX Announces Second Quarter 2023 Operating and Financial Results
4:03pm
8-K
EX-10.1
evamiu9
5 Jul 23
MIMEDX Appoints Doug Rice as Chief Financial Officer
9:02am
8-K
EX-10.1
3ca2ww840
14 Jun 23
Departure of Directors or Certain Officers
4:23pm